Key result
Levosimendan further reduces in vitro platelet reactivity in CAD patients on antiplatelet therapy.
Why the study?
With expanding clinical applications of levosimendan, it is essential to determine whether levosimendan and its metabolites affect platelet activation mechanisms to balance bleeding and thrombosis risks.
Does the in vitro addition of levosimendan and its metabolites (OR-1855 and OR-1896) further inhibit platelet reactivity and aggregation in blood samples from patients with coronary artery disease receiving aspirin or dual antiplatelet therapy (aspirin and clopidogrel)?
Does the in vitro addition of levosimendan and its metabolites (OR-1855 and OR-1896) further inhibit platelet reactivity and aggregation in blood samples from patients with coronary artery disease receiving aspirin or dual antiplatelet therapy (aspirin and clopidogrel)?
This in vitro pilot study demonstrates that levosimendan and its active metabolites exert an additive inhibitory effect on ADP-induced platelet aggregation in blood from CAD patients on single or dual antiplatelet therapy, suggesting a potential increased risk of bleeding in clinical settings.
Answers are grounded in this paper and cite their sources.
May raise bleeding risk when levosimendan is added to antiplatelet therapy in CAD; hypothesis-generating and requires in vivo confirmation.
Levosimendan is used for the short-term treatment of severe heart failure or other cardiac conditions. The area of existing clinical applications for levosimendan has increased significantly. This study aimed to assess whether levosimendan and its metabolites impact the mechanisms related to platelet activation. In this study, we included patients with coronary artery disease receiving antiplatelet therapy. We analyzed the pharmacodynamic profile using three independent methods to assess platelet activity. The results of the conducted studies indicate a mechanism of levosimendan that affects the function of platelets, causing higher inhibition of platelet receptors and, thus, their aggregation. It is essential to clarify whether levosimendan may affect platelets due to the need to maintain a balance between bleeding and thrombosis in patients treated with levosimendan. This is especially important in the case of perioperative bleeding. This study was conducted in vitro; the research should be continued and carried out in patients to check the complete pharmacokinetic and pharmacodynamic profile.
No takes yet. Share an insight, caveat, or question.
Sikora et al. (2024) studied Coronary artery disease receiving antiplatelet therapy (n=20). In vitro addition of levosimendan and its metabolites (OR-1896 and OR-1855) to venous blood vs. Baseline control blood sample (treated with aspirin alone or aspirin plus clopidogrel without levosimendan or metabolites) was evaluated on In vitro ADP-induced platelet reactivity assessed by multiple-electrode aggregometry (MEA), vasodilator-stimulated phosphoprotein (VASP) assay, and light transmission/impedance aggregometry (LTA). Levosimendan and its metabolites further reduced in vitro ADP-induced platelet reactivity on MEA in blood from CAD patients on aspirin or DAPT.
Synapse has enriched 10 related papers. Consider them for comparative context: